BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 17433471)

  • 1. Are we misunderstanding beta-blockers.
    Cruickshank JM
    Int J Cardiol; 2007 Aug; 120(1):10-27. PubMed ID: 17433471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-blockers and heart failure.
    Cruickshank JM
    Indian Heart J; 2010; 62(2):101-10. PubMed ID: 21180298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The case for beta-blockers as first-line antihypertensive therapy.
    Cruickshank JM
    J Hypertens Suppl; 1992 Jun; 10(3):S21-7. PubMed ID: 1353111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Beta-Blockers in the Treatment of Hypertension.
    Cruickshank JM
    Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-blockers and diabetes: the bad guys come good.
    Cruickshank JM
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):457-70. PubMed ID: 12652116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular protection using beta-blockers: a critical review of the evidence.
    Bangalore S; Messerli FH; Kostis JB; Pepine CJ
    J Am Coll Cardiol; 2007 Aug; 50(7):563-72. PubMed ID: 17692739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Do beta-blockers prevent coronary events in hypertensive patients?].
    Diévart F; Ragot S; Julien J; Herpin D
    Arch Mal Coeur Vaiss; 2005 Sep; 98(9):881-8. PubMed ID: 16231574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Present trends and controversies in the use of beta-blockers in cardiovascular diseases].
    Spoladore R; Fragasso G; Montanaro C; Maranta F; Torlasco C; Gerosa S; Margonato A
    Recenti Prog Med; 2010 Nov; 101(11):429-41. PubMed ID: 21197763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Critical analysis of beta blockers in heart failure: certainty and incompleteness].
    Rapezzi C; Branzi A
    Ital Heart J Suppl; 2000 Aug; 1(8):1003-10. PubMed ID: 10993006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving role of β-adrenergic receptor blockers in managing hypertension.
    Poirier L; Lacourcière Y
    Can J Cardiol; 2012 May; 28(3):334-40. PubMed ID: 22595449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in betablocking drugs in cardiovascular therapy.
    Iisalo E; Heikkilä J
    Ann Clin Res; 1988; 20(5):324-33. PubMed ID: 2905877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiovascular risk stratification. Systolic, diastolic or pulse pressure?].
    Pede S; Lombardo M
    Ital Heart J Suppl; 2001 Apr; 2(4):356-8. PubMed ID: 19397006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ; Anderson S
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of beta-blockade and ACE inhibitors in the treatment of hypertension.
    Prichard BN; Saul PA
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S81-5. PubMed ID: 11527141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Elderly heart failure patients and the role of beta-blocker therapy].
    Middeljans-Tijssen CW; Jansen RW
    Tijdschr Gerontol Geriatr; 2006 Apr; 37(2):67-77. PubMed ID: 16704019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ; Schalekamp MA
    Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.